Selected research
Industry Research
Kidney Cancer Therapy Industry Research Report 2026
Market perspective
The global Kidney Cancer Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Kidney Cancer Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Kidney Cancer Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Kidney Cancer Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Kidney Cancer Therapy include Eisai, Novartis, Merck, Roche, Pfizer, Bayer, Amgen, Sun Pharmaceutical and Hikma Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Kidney Cancer Therapy market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Kidney Cancer Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Kidney Cancer Therapy Market by Company
Eisai
Novartis
Merck
Roche
Pfizer
Bayer
Amgen
Sun Pharmaceutical
Hikma Pharmaceuticals
Exelixis
Bristol-Myers Squibb
Aveo Pharmaceuticals
Kidney Cancer Therapy Segment by Type
Targeted Therapy
Immunotherapy
Surgery
Other
Kidney Cancer Therapy Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
Kidney Cancer Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Kidney Cancer Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy
- Immunotherapy
- Surgery
- Other
Applications
- Renal Cell Carcinoma (RCC)
- Transitional Cell Carcinoma (TCC)
Companies covered
- Eisai
- Novartis
- Merck
- Roche
- Pfizer
- Bayer
- Amgen
- Sun Pharmaceutical
- Hikma Pharmaceuticals
- Exelixis
- Bristol-Myers Squibb
- Aveo Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Kidney Cancer Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Targeted Therapy
- 2.2.3 Immunotherapy
- 2.2.4 Surgery
- 2.2.5 Other
- 2.3 Kidney Cancer Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Renal Cell Carcinoma (RCC)
- 2.3.3 Transitional Cell Carcinoma (TCC)
- 2.4 Assumptions and Limitations
3 Kidney Cancer Therapy Breakdown Data by Type
- 3.1 Global Kidney Cancer Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Kidney Cancer Therapy Forecasted Market Size by Type (2027-2032)
4 Kidney Cancer Therapy Breakdown Data by Application
- 4.1 Global Kidney Cancer Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Kidney Cancer Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Kidney Cancer Therapy Market Perspective (2021-2032)
- 5.2 Global Kidney Cancer Therapy Growth Trends by Region
- 5.2.1 Global Kidney Cancer Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Kidney Cancer Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Kidney Cancer Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Kidney Cancer Therapy Market Dynamics
- 5.3.1 Kidney Cancer Therapy Industry Trends
- 5.3.2 Kidney Cancer Therapy Market Drivers
- 5.3.3 Kidney Cancer Therapy Market Challenges
- 5.3.4 Kidney Cancer Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Kidney Cancer Therapy Players by Revenue
- 6.1.1 Global Top Kidney Cancer Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Kidney Cancer Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Kidney Cancer Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Kidney Cancer Therapy Head Office and Area Served
- 6.4 Global Kidney Cancer Therapy Players, Product Type & Application
- 6.5 Global Kidney Cancer Therapy Manufacturers Established Date
- 6.6 Global Kidney Cancer Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Kidney Cancer Therapy Market Size (2021-2032)
- 7.2 North America Kidney Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Kidney Cancer Therapy Market Size by Country (2021-2026)
- 7.4 North America Kidney Cancer Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Kidney Cancer Therapy Market Size (2021-2032)
- 8.2 Europe Kidney Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Kidney Cancer Therapy Market Size by Country (2021-2026)
- 8.4 Europe Kidney Cancer Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Kidney Cancer Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Kidney Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Kidney Cancer Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Kidney Cancer Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Kidney Cancer Therapy Market Size (2021-2032)
- 10.2 South America Kidney Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Kidney Cancer Therapy Market Size by Country (2021-2026)
- 10.4 South America Kidney Cancer Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Kidney Cancer Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Kidney Cancer Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Kidney Cancer Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Kidney Cancer Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eisai
- 12.1.1 Eisai Company Information
- 12.1.2 Eisai Business Overview
- 12.1.3 Eisai Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.1.4 Eisai Kidney Cancer Therapy Product Portfolio
- 12.1.5 Eisai Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.2.4 Novartis Kidney Cancer Therapy Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.3.4 Merck Kidney Cancer Therapy Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.4.4 Roche Kidney Cancer Therapy Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.5.4 Pfizer Kidney Cancer Therapy Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.6.4 Bayer Kidney Cancer Therapy Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 Amgen
- 12.7.1 Amgen Company Information
- 12.7.2 Amgen Business Overview
- 12.7.3 Amgen Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.7.4 Amgen Kidney Cancer Therapy Product Portfolio
- 12.7.5 Amgen Recent Developments
- 12.8 Sun Pharmaceutical
- 12.8.1 Sun Pharmaceutical Company Information
- 12.8.2 Sun Pharmaceutical Business Overview
- 12.8.3 Sun Pharmaceutical Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.8.4 Sun Pharmaceutical Kidney Cancer Therapy Product Portfolio
- 12.8.5 Sun Pharmaceutical Recent Developments
- 12.9 Hikma Pharmaceuticals
- 12.9.1 Hikma Pharmaceuticals Company Information
- 12.9.2 Hikma Pharmaceuticals Business Overview
- 12.9.3 Hikma Pharmaceuticals Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.9.4 Hikma Pharmaceuticals Kidney Cancer Therapy Product Portfolio
- 12.9.5 Hikma Pharmaceuticals Recent Developments
- 12.10 Exelixis
- 12.10.1 Exelixis Company Information
- 12.10.2 Exelixis Business Overview
- 12.10.3 Exelixis Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.10.4 Exelixis Kidney Cancer Therapy Product Portfolio
- 12.10.5 Exelixis Recent Developments
- 12.11 Bristol-Myers Squibb
- 12.11.1 Bristol-Myers Squibb Company Information
- 12.11.2 Bristol-Myers Squibb Business Overview
- 12.11.3 Bristol-Myers Squibb Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.11.4 Bristol-Myers Squibb Kidney Cancer Therapy Product Portfolio
- 12.11.5 Bristol-Myers Squibb Recent Developments
- 12.12 Aveo Pharmaceuticals
- 12.12.1 Aveo Pharmaceuticals Company Information
- 12.12.2 Aveo Pharmaceuticals Business Overview
- 12.12.3 Aveo Pharmaceuticals Revenue in Kidney Cancer Therapy Business (2021-2026)
- 12.12.4 Aveo Pharmaceuticals Kidney Cancer Therapy Product Portfolio
- 12.12.5 Aveo Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst